DR. STUART P WEISBERG, M.D/ PHD
Student, Health Care at 168 St, New York, NY
License number
New York 251752
Category
Student, Health Care
Type
Student in an Organized Health Care Education/Training Program
Address
Address
622 W 168Th St, New York, NY 10032
Phone
(917) 541-4085
Personal information
See more information about STUART P WEISBERG at radaris.comName
Address
Phone
1177 E 98Th St APT 5J, Brooklyn, NY 11236
11 Wooleys Ln APT 2C, Great Neck, NY 11023
14 Duesenberg Dr, East Norwich, NY 11732
19 Knapp Rd, Pound Ridge, NY 10576
390 Ocean Pkwy APT 3F, Brooklyn, NY 11218
Professional information
President At Smw Communications
Location:
Greater New York City Area
Industry:
Printing
Methods Of Treatment And Prevention Of Diet-Induced Obesity And Sequelae Thereof
US Patent:
2011020, Aug 18, 2011
Filed:
Aug 11, 2008
Appl. No.:
12/672869
Inventors:
Christopher L. Karp - Cincinnati OH, US
Stuart P. Weisberg - New York NY, US
Senad Divanovic - Cincinnati OH, US
Stuart P. Weisberg - New York NY, US
Senad Divanovic - Cincinnati OH, US
Assignee:
Children's Hospital Medical Center - Cincinnati OH
International Classification:
A61K 39/395, A61K 38/00, A61K 31/7105, G01N 33/53, A61P 3/04
US Classification:
4241301, 514 48, 514 44 A, 435 721
Abstract:
Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at risk for developing diet-induced obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one inhibitor of RP 105 and/or MD-I activity. Also disclosed are methods of identifying compounds that inhibit development of diet-induced obesity and/or one or more sequelae thereof. In some aspects, these methods comprise: providing at least one first cell comprising TLR4, MD-2. RP105. MD-K and a TLR4-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with lipopolysaccharide and with a candidate compound; and determining a level of expression of the reporter in the presence of the LPS and the candidate compound, in some aspects, these methods comprise: providing at least one first cell comprising TLR2, TLR1, TLR6, MD-2, RP H/S, MD-K and a TLR2-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with a lipopeptide ligand of TLR2 and with a candidate compound, and determining a level of expression of the reporter in the presence of the lipopeptide ligand of TLR2 and the candidate compound
Selective Proteasome Inhibitors For Treating Diabetes
US Patent:
2010024, Sep 23, 2010
Filed:
Nov 13, 2007
Appl. No.:
12/514682
Inventors:
Drew Tortoriello - Jersey City NJ, US
Stuart P Weisberg - New York NY, US
Stuart P Weisberg - New York NY, US
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
A61K 38/28, A61K 38/08, A61K 38/06, A61K 38/07, A61K 31/4015, A61K 31/353, A61K 31/7048, A61K 31/4995, A61K 38/16, A61K 31/12, A61K 31/195, A61K 31/407, A61K 31/18, A61K 38/10, A61K 31/192, A61P 5/50, A61P 3/10, A61P 29/00
US Classification:
514 67, 514 218, 514 219, 514425, 514456, 514 27, 514250, 514 212, 514679, 514562, 514421, 514604, 514 215, 514569
Abstract:
Methods of modulating chronic low-grade inflammation are provided. More particularly, methods of treating diabetes, such as for example, type-2 diabetes mellitus, in a mammal by administering an effective amount of a selective proteasome inhibitor are provided. Also provided are unit dosage forms of such inhibitors.